FMP
Paysign Gets Price Target Bump as Plasma Network Expands Sharply
Jun 13, 2025 4:41 PM - Davit Kirakosyan
Image credit: FMP
DA Davidson raised its price target on Paysign (NASDAQ:PAYS) to $8 from $7 while reaffirming a Buy rating, following a major boost to the company's plasma donation center footprint.
Paysign recently announced the addition of 132 established plasma centers through an expanded partnership with a key plasma collection provider. This expansion brings the company's total to 613 locations, up 27% from the 484 centers it serviced at the close of the first quarter of 2025.
In response to this growth, the firm revised its financial outlook upward for both 2025 and 2026 and initiated forecasts for 2027. The increase in plasma center coverage signals stronger future revenue potential and supports continued confidence in Paysign’s business trajectory.
Other Blogs
Nov 22, 2024 5:08 AM - Parth Sanghvi
Fundamental Analysis: Principles, Types, and How to Use It
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...
Dec 17, 2024 8:58 AM - Sanzhi Kobzhan
Examining Tesla’s Financial Health Using FinancialModelingPrep’s Ratios API
Tesla, one of the world’s most talked-about electric vehicle manufacturers, attracts a lot of attention from investors and market watchers. By examining a snapshot of Tesla’s financial ratios—such as those provided by FinancialModelingPrep’s Ratios API—we can get a clearer picture of the company’s f...
Dec 22, 2024 7:59 AM - Sanzhi Kobzhan
Two great Software Platform Stocks Similar to Palantir (PLTR)
When it comes to cutting-edge software and data analytics, Palantir Technologies (NYSE: PLTR) is often front and center. But for many investors, it’s important to consider alternative or complementary stocks in the same sector that may offer robust growth potential. As PLTR looks expensive (overvalu...
